baber/WOPTO huggingface dataset:
Patent NZ-584111-A (NZ)
Title: Evaluating a severity change indicator of a respiratory insufficiency condition
Inventor: SCHINDHELM KLAUS HENRY
IPC: A61B5/08
Filed: 2010-03-22
Abstract: Disclosed is a device for monitoring a patient to evaluate a respiratory insufficiency condition of the patient. The device comprises a transducer to generate a signal representative of the pressure delivered by a flow generator; and a processor, coupled with the transducer. The processor is configured to control an evaluation of a severity change indicator based on a measure of pressure derived from the signal representative of pressure. The indicator represents information about a change in severity of a respiratory insufficiency condition of the patient.
Patent NZ-585652-A (NZ)
Title: Amide compounds as boosters of antivirals
Inventor: JONCKERS TIM HUGO MARIA
IPC: C07D417/14
Filed: 2008-12-05
Abstract: Disclosed herein are compounds of formula (I), wherein the substituents are as defined within the specification, that have CYP450 inhibiting properties and are useful as boosters of certain drugs, i.e. they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered. Also disclosed is the use of said compounds as improvers of the bioavailability of certain drugs, i.e.darunavir. Methods for the preparation of the compounds and pharmaceutical compositions are further disclosed.
Patent NZ-593061-A (NZ)
Title: Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -azetidine-3-carboxylic acid
Inventor: RIEGERT CHRISTIAN
IPC: A61K31/397
Filed: 2009-12-16
Abstract: 593061 This disclosure relates to a hemifumarate salt of 1-(4-{ 1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl} -2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present disclosure also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
Patent NZ-593449-A (NZ)
Title: Respiratory apparatus with a pair of delivery conduits
Inventor: KENYON BARTON JOHN
IPC: A61M16/00
Filed: 2009-01-30
Abstract: An apparatus for delivering a flow of pressurized breathable gas to a patient, comprises a flow generator 4 to generate the flow of pressurized breathable gas, a casing 6 to contain the flow generator 4 where the casing 6 is configured to engage the top of the patient's head 2, a power supply 66 for the flow generator 4, a pair of delivery conduits 8 configured to convey the flow of pressurized breathable gas, and a patient interface 12. The pair of delivery conduits 8 are configured to extend from the flow generator 4 and along the sides of the patient's face to the patient interface 12 in use. The patient interface 12 receives the flow of pressurized breathable gas from the pair of delivery conduits 8 and delivers it to the patient's airways.
Patent NZ-593724-A (NZ)
Title: Stainless steel flux-cored welding wire for the welding of steel sheets with a composition to reduce cracking and increase corrosion resistance and ductility
Inventor: KODAMA SHINJI
IPC: B23K9/173
Filed: 2009-06-26
Abstract: Disclosed is a stainless steel flux-cored welding wire for the welding of galvanized steel sheets. The wire does not cause zinc embrittlement cracking, can give welds excellent in corrosion resistance and ductility, and attains excellent workability in welding. A process for welding with the welding wire is further provided. The welding wire is characterized in that the sheath and the flux contain, as metal or alloying components and in a total amount based on the total mass of the wire, C: 0.01 to 0.05%, Si: 0.1 to 1.5%, Mn: 0.5 to 3%, Ni: 7 to 10% and Cr: 26 to 30% with the F value falling within the range of 30 to 50. The flux contains, as slag formers, TiO2: 3.8 to 6.8%, SiO2: 1.8 to 3.2%, ZrO2: 1.3% or below, and Al2O3: 0.5% or below, that the total amount of these slag formers and the other slag formers is 7.5 to 10.5%. TiO2 accounts for 50 to 65% of the total amount of all the slag formers. The balance of the sheath and the flux consists of Fe and unavoidable impurities.
Patent NZ-595027-A (NZ)
Title: Network commercial transactions
Inventor: JOHNSON BRUCE E
IPC: G06Q20/32
Filed: 2006-04-19
Abstract: In a system that includes computing devices for a consumer, a merchant, and at least one payment provider, a computer implemented method is disclosed performed by the computing devices for the consumer, the merchant, and the at least one payment provider of providing a secure commercial transaction for online purchase of services, goods, or both, by establishing a three-way exchange of data between the computing devices for the consumer, the merchant, and the at least one payment provider. The method comprising a consumer computing device (110) sending an online request to a merchant computing device to purchase one or more services, goods, or both, offered by the merchant. The consumer receives billing information from the merchant (140), which includes a cost associated with the purchase of the one or more services, goods, or both and the consumer sends the billing information to at least one payment provider computing device (130). The at least one payment provider stores the billing information and the consumer requests that the at least one payment provider provide a payment token as proof of an ability of the consumer to pay the cost of the one or more services, goods, or both. The payment token includes the billing information, and the consumer has a billing account with the at least one payment provider. The consumer receives from the at least one payment provider the payment token and the payment token uniquely identifies the authorization of payment for the cost without revealing sensitive information about the billing account for the consumer to the merchant. The consumer sends the payment token to the merchant and prior to finalizing the request from the consumer to purchase the one or more services, goods, or both, the merchant sends the payment token to the at least one payment provider to validate payment with the at least one payment provider. The at least one payment provider compares the billing information within the payment token received from the merchant to the stored billing information received from the consumer to validate the payment token. The merchant receives acknowledgment from the at least one payment provider that the payment token has been validated and the merchant finalizes the request to purchase the one or more services, goods, or both by sending the acknowledgement to the consumer and the consumer receives the acknowledgement of the validity of the payment token indicating appropriate transfer of the one or more services, goods, or both, from the merchant to the consumer.
Patent NZ-597171-A (NZ)
Title: Polymers containing heterocyclic 3-ring compounds and iodine-containing compounds
Inventor: BOTTCHER ANDREAS
IPC: C08K5/00
Filed: 2010-06-28
Abstract: Abstract 597171 A polymer composition comprising at least an aziridine compound and an iodoalkynyl compound or a compound in which one or more iodine atoms are covalently bonded to singly or doubly bonded carbon atoms. Such compositions are useful in coatings and articles where the inhibition of biological fouling is desirable. Preferred Aziridines are trimethylolpropane tris[3-(1-aziridinyl)propionate), trimethylolpropane tris[3-(2-methyl-1-aziridinyl)propionate], trimethylolpropane tris[2-aziridinylbulyrate], pentaerythritol tris-[3-(1-aziridinyl)propionate) and pentaerythritol tetrakis-[3-(1-aziridinyl)propionate). Preferred iodine containing compounds include diiodomethyl p-tolylsulphone, diiodomethyl p-chlorophenyl sulphone, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-(3-iodopropargyl)-6-chlorobenzoxazol-2-one, 3-iodo-2-propynyl alcohol, 3-bromo-2,3-diiodo-2-propenyl ethylcarbamate, 3-iodo-2-propynyl n-hexylcarbamate or 3-iodo-2-propynyl cyclohexyl-carbamate.
Patent NZ-597228-A (NZ)
Title: Absorption of volatile organic compounds derived from organic matter
Inventor: ROWSELL ELIZABETH
IPC: A23L5/20
Filed: 2010-07-02
Abstract: The present invention relates to the use of palladium doped ZSM-5 to adsorb volatile organic compounds (VOCs) derived from organic matter, whereinthe Si:Al ratio of the ZSM-5 is less than 5 or equal to 100:1, and wherein the palladium doped ZSM-5 is used in an environment comprising less than 10 vol% of oxygen.
Patent NZ-598965-A (NZ)
Title: Method for reducing pistillate flower abortion in plants using at least one strobilurin
Inventor: NITSCHE JORGE PEDRO
IPC: A01N37/44
Filed: 2010-09-20
Abstract: Patent No. 598965 Disclosed is a method for reducing pistillate flower abortion in plants, comprising repeatedly treating the plant, plant parts, the locus where the plant is growing or is intended to grow with at least one strobilurin at application rates between 125g and 750g of active ingredient per hectare per treatment, wherein the application is carried out during the flowering period of the plant. Also disclosed is the use of at least one strobilurin for reducing pistillate flower abortion in plants.
Patent NZ-608895-A (NZ)
Title: Construction of a gripping fabric
Inventor: CHERNESKI JAMES PAUL
IPC: D06N7/00
Filed: 2011-08-31
Abstract: 608895 Disclosed is gripping fabric for incorporating into garments, such as socks (403), which provides grip between a body part of a wearer, such as their foot, and an external contact surface, such as a floor. The fabric comprises a fabric structure (401) having an inner surface, which is proximal to a user contact surface, and an outer surface, which is distal to the user contact surface. A gripping material (402) selectively applied to the inner surface or the outer surface to provide adherence to the user contact surface and external contact surface. A gripping garment, a method of constructing a gripping fabric, a method of applying a gripping material to a fabric structure, and a method of constructing a gripping garment are also disclosed.
Patent NZ-609313-A (NZ)
Title: Cyclopropane compounds
Inventor: TERAUCHI TARO
IPC: C07D471/04
Filed: 2011-09-20
Abstract: Disclosed are 2-(3-phenyl)-N-(pyridinyl)-2-[(methylpyrimidin-5-yl)oxymethyl]cyclopropane carboxamide derivatives as represented by the general formula (IV), or a pharmaceutically acceptable salt thereof, wherein Q represents -CH- or a nitrogen atom, R1a and R1b each independently represent a alkyl, haloalkyl, hydroxy-alkyl or alkoxy-alkyl; R1c represents a hydrogen atom or a hydroxyl group; R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, alkyl, alkoxy, haloalkyl or a cyano group; and R3a, R3b, R3c and R3d each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, alkyl, alkoxy, haloalkyl, alkoxy-alkyl, a cyano group or a cyano-alkyl group. Representative compounds include (1R,2S)-2-{ [(2,4-dimethylpyrimidin-5-yl)oxy]methyl} -N-(5-fluoropyridin-2-yl)-2-phenylcyclopropanecarboxamide, (1R,2S)-2-{ [(2,4-dimethylpyrimidin-5-yl)oxy]methyl} -N-(5-fluoro-4-methylpyridin-2-yl)-2-phenylcyclopropanecarboxamide, (1R,2S)-2-{ [(2,4-dimethylpyrimidin-5-yl)oxy]methyl} -N-(5-fluoro-4-methylpyridin-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide, (1R,2S)-2-{ [(2,4-dimethylpyrimidin-5-yl)oxy]methyl} -2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide, (1R,2S)-2-(3,5-difluorophenyl)-2-{ [(2,4-dimethylpyrimidin-5-yl)oxy]methyl} -N-(5-fluoro-4-methylpyridin-2-yl)cyclopropanecarboxamide and (1R,2S)-2-{ [(4-ethyl-2-methylpyrimidin-5-yl)oxy]methyl} -2-(3-fluorophenyl)-N-(pyridin-2-yl)cyclopropanecarboxamide. Also disclosed is a compound as defined above or a pharmaceutically acceptable salt thereof for use as an active ingredient of a pharmaceutical composition, for the treatment of sleep disorder (and particularly insomnia) for which orexin receptor antagonism is effective.
Patent NZ-622023-A (NZ)
Title: Container liquid leak inspection device
Inventor: KOBAYASHI TOSHIYA
IPC: G01M3/26
Filed: 2012-09-07
Abstract: A container liquid leak inspection device comprises a conveyance device 1 which conveys a sealed container (A) having flexibility which is filled with a fluid, a pressurizing device (2) which applies pressure to the sealed container (A) from outside the container while it is being conveyed, an image capture device (3) which captures an image of the sealed container (A) together with a background thereof while pressure applied to the container, and determination device (4) which determines whether there is a liquid leak present in the sealed container (A) on the basis of the image information which is acquired with the image capture device (3). The determination device (4) is configured to assess whether image information of a liquid discharge which is discharged into air from the sealed container (A) is included in the background image information, and to carry out a determination that a liquid leak is present in the sealed container (A) if it is assessed that the liquid discharge image information is included in the background image information. If a leak is determined a controller 6 may signal a pusher 5 to remove the leaking container from the main conveyor path 1a, 1c.
Patent NZ-622118-A (NZ)
Title: Cardiovascular risk event prediction and uses thereof
Inventor: GILL ROSALYNN DIANNE
IPC: G01N33/52
Filed: 2012-09-28
Abstract: A method for determining the likelihood that an individual has increased risk of a Cardiovascular Event (CV) event comprises detecting, in a biological sample removed from an individual, biomarker values that each correspond to one of at least N biomarkers selected from Table 1 (defined in the specification), and determining the likelihood that the individual has increased risk for a CV event based on said biomarker values with N being 2 to 155 and one of the at least N biomarkers selected from Table 1 is CCL18.
Patent NZ-629204-A (NZ)
Title: Anti-vla1 (cd49a) antibody pharmaceutical compositions
Inventor: FOWLER ADAM JEREMY
IPC: C07K16/28
Filed: 2013-02-14
Abstract: Disclosed is an aqueous antibody pharmaceutical composition comprising an anti-VLA-I (anti-Very Late Antigen-I) antibody at a concentration of about 100 mg/ml to about 225 mg/ml and at least one buffer, wherein said anti-VLA-I antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:4 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5, and wherein the aqueous pharmaceutical composition is stable after storage at 2°C to 8°C for at least 3 years.
Patent NZ-630839-A (NZ)
Title: Compositions, methods and uses for dengue virus serotype-4 constructs
Inventor: LIVENGOOD JILL A
IPC: C12N15/40
Filed: 2013-11-08
Abstract: Disclosed is a nucleic acid molecule comprising a chimeric dengue construct comprising nucleic acid sequences encoding nonstructural proteins and one or more structural proteins from a live, attenuated dengue-2 virus and encoding one or more structural proteins from a dengue-4 virus, wherein the chimeric construct comprises one or more mutations comprising: a mutation in an envelope protein at position 417 of dengue-4, wherein the mutation changes glutamic acid to a positively charged residue a mutation in the capsid protein at position 107 of the dengue-2 virus in the dengue-4/dengue-2 chimera, wherein the mutation changes to an aromatic residue a mutation in NS4A at position 17 in the live, attenuated dengue-2 virus, wherein the live, attenuated dengue-2 virus is a modified dengue-2 PSK-53 virus
Patent NZ-703653-A (NZ)
Title: Anti-fap antibodies and methods of use
Inventor: FREIMOSER-GRUNDSCHOBER ANNE
IPC: C07K16/40
Filed: 2011-08-09
Abstract: Disclosed is an antibody that specifically binds to Fibroblast Activation Protein (FAP), wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 299, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 205.
Patent NZ-712804-A (NZ)
Title: Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction
Inventor: WHITCUP SCOTT M
IPC: A61K9/00
Filed: 2014-04-09
Abstract: The present invention is directed to sustained release compositions comprising polylactides and bimatoprost or a bimatoprost analogue. The compositions may be in the form of an implant and are useful for localized fat reduction in both cosmetic and therapeutic applications. The active agent may be released from the compositions into a fat deposit over a duration exceeding 100 days.
Patent NZ-721089-A (NZ)
Title: Angiotensin ii alone or in combination for the treatment of hypotension
Inventor: CHAWLA LAKHMIR
IPC: A61K38/08
Filed: 2014-12-18
Abstract: The present invention relates, e.g., to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-2.0 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.
Patent NZ-730866-A (NZ)
Title: Condition responsive indication assembly and method
Inventor: DEY SAIKAT
IPC: G05B23/02
Filed: 2015-03-16
Abstract: A portable communications device transportable to remote locations by an individual includes a control unit. A biometric sensor is electrically connected to the control unit. The biometric sensor senses a condition of the individual and creates and transmits a signal to the control unit. An environmental sensor is electrically connected to the control unit. The environmental sensor senses an environmental condition local to the individual and creates and transmits a signal to the control unit. A communications unit is electrically connected to the control unit. It receives the signals from the control unit and transmits them away from the remote locations.
Patent NZ-732172-A (NZ)
Title: Portable ballet bar exercise device
Inventor: KWO JENNIE
IPC: A63B1/00
Filed: 2015-11-12
Abstract: Present free-standing ballet bar exercise devices have limitations. A need exists for an improved portable ballet bar exercise device that is adjustable in height, easier to assemble, collapse, transport, and store than the prior art devices. A need also exists for a portable ballet bar with an improved structural design. A need further exists for a portable ballet bar with fewer components, to simplify the manufacturing and assembly process. A need moreover exists for a portable ballet bar that is modular in nature such that it can be used as a single stand-alone unit or a single wall-mountable unit, or can be combined with an identical unit to form a double stand-alone unit or a double wall-mountable unit. Multiple embodiments of a portable ballet bar exercise device are disclosed. In certain embodiments, the portable ballet bar exercise device is modular in nature such that it can be used as a single stand-alone unit or a single wall-mountable unit, or can be combined with an identical unit to form a double stand-alone unit or a double wall-mountable unit.
Patent NZ-740301-A (NZ)
Title: Systems and methods for improved focus tracking using a hybrid mode light source
Inventor: DAVID HARGIS
IPC: H01S5/30
Filed: 2018-02-27
Abstract: Designers of pre-existing scanning systems use a multi-beam focus track system to determine focus distances for a given sample are constantly striving to improve focus accuracy and the speed with which the system can determine the focus settings for a given sample. The multi-beam system focuses two beams onto the sample using objective lens. The focus beams are reflected from the surface of the sample and reflected beams are directed toward an image sensor. Reflected beams form spots on the image sensor and the distance between the spots can be used to determine the focus distance. Improving accuracy is important in that it can allow the system to achieve better results. Reducing latency can be an important consideration because it can allow the system to reach a focus determination more quickly, thus allowing the system to complete scanning operations faster. Accordingly, disclosed herein is provided systems and methods including an imaging system that may include a laser diode source; an objective lens positioned to direct a focus tracking beam from the light source onto a location in a sample container and to receive the focus tracking beam reflected from the sample; and an image sensor that may include a plurality of pixel locations to receive focus tracking beam that is reflected off of the location in the sample container, where the reflected focus tracking beam may create a spot on the image sensor. Some examples may further include a laser diode light source that may be operated at a power level that is above a power level for operation at an Amplified Spontaneous Emission (“ASE”) mode, but below a power level for single mode operation.
Patent NZ-741780-A (NZ)
Title: Anti-htra1 antibodies and methods of use thereof
Inventor: KELLEY ROBERT
IPC: C07K16/40
Filed: 2016-10-27
Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies), isolated nucleic acids encoding said anti-HtrA1 antibodies, compositions of said anti-HtrA1 antibodies, and methods of making said anti-HtrA1 antibodies. The anti-HtrA1 antibodies of the invention have a high binding affinity for HtrA1 (e.g., a KD of about 550 pM or lower) and inhibit HtrA1 activity and can be used, for example, in therapeutic and diagnostic methods, e.g., methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders, including age-related macular degeneration. The anti-HtrA1 antibodies comprise: heavy chain CDRs DSEXH (wherein X is M or L), GVDPETXGAAYNQKFKG (wherein X is E or D), and GYDYDYALDY; and light chain CDRs RASSSVXFIH (wherein X is E or N), ATSXLAS (wherein X is N, H or E), and QQWXSXPWT (wherein the first X is S or Y, and the second X is A or N).
Patent NZ-743271-A (NZ)
Title: Relocalization systems and methods
Inventor: Schroeder Brigit
IPC: G06F3/03
Filed: 2016-12-05
Abstract: The present disclosure relates to the localisation of pose-sensitive systems. One disclosed embodiment relates to a method of determining a pose of an image capture device. The method includes capturing an image using an image capture device. The method also includes generating a data structure corresponding to the captured image. The method further includes comparing the data structure with a plurality of known data structures to identify a most similar known data structure. The method further includes reading metadata corresponding to the most similar known data structure to determine a pose of the image capture device. The method further includes training a neural network by mapping a plurality of known images to the plurality of known data structures. The data structure is an N dimensional vector. The step of generating the data structure corresponding to the captured image comprises using a neural network to map the captured image to the N dimensional vector. Each known image of the plurality has respective metadata including pose data. The step of training the neural network comprises accessing a database of the known images annotated with the respective metadata, decreasing a first Euclidean distance between first and second known N dimensional vectors respectively corresponding to matching first and second known images in an N dimensional space, and increasing a second Euclidean distance between first and third known N dimensional vectors respectively corresponding to non-matching first and third known images in the N dimensional space.